Mantle cell lymphoma (MCL) responds poorly to standard chemotherapy regimens used in non-Hodgkin's lymphoma. As a result, a combination of high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is being investigated in patients with MCL. So far, however, there is no evidence for longterm remission -believed, in part, to be due to contamination of the transfusion product with residual cancer cells. Many ex-vivo purging methods have been developed to remove tumour cells, but these are complicated, time-consuming and expensive. This study describes an in vivo purging method using rituximab to produce a tumour-free stem cell product for re-infusion following HDT. The regimen is split into a purging phase and a myeloablative phase, which together consist of four-step high-dose sequential chemotherapy (sHDT) and six infusions of rituximab immunotherapy. The sHDT comprises cyclophosphamide, cytosine arabinoside, melphalan and mitoxantrone plus melphalan. There are two separate stem cell harvests and three reinfusions. In a pilot study 28 patients with untreated MCL received standard chemotherapy followed by sHDT with rituximab in vivo purging. Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable patients, 100% lymphoma-negative harvests were achieved following in vivo purging. PCR analyses of the bone marrow following the four-step high-dose regimen with purging and transplantation showed that all patients achieved molecular remission. After a median follow-up of 22 months (range 10-42 months), two patients had died while 26 were alive and disease free. This method allows efficient in vivo purging in the context of an effective chemotherapy regimen and may have a role as first-line therapy in MCL patients who respond poorly to standard treatment.
Mantle cell lymphoma (MCL) comprises around 5-8% of all cases of non-Hodgkin's lymphoma (NHL). It is a distinct clinical entity, recognised by the Revised EuropeanAmerican Classification of Lymphoid Neoplasms (REAL) and World Health Organisation (WHO) classification systems for NHL.
1,2 MCL is a CD5 + , CD20 + malignancy, characterised by a t (11:14) translocation causing over expression of cyclin D1 and cell cycle dysregulation. 3, 4 The malignancy has a male predominance of greater than 2:1 and the median age of onset is 58 years. 5 MCL is usually disseminated at diagnosis and responds poorly to standard chemotherapy regimens used in NHL. Analyses of patients with MCL in clinical trials indicate a median disease-free survival of just 1 year and overall survival of only 3 years. 6 Clearly, patients with MCL need an alternative treatment to conventional chemotherapy, and therefore high-dose chemotherapy with autologous stem cell transplantation (ASCT) has been considered for these patients.
Pilot studies of ASCT have given encouraging results with complete response rates of 100% and 2-year progression-free survival rates of 30-60%. [7] [8] [9] The studies, however, had low patient numbers and short follow-up times. Subsequent long-term follow-up has generally revealed a poor clinical outcome, with no evidence for long-term remission (Figure 1 ). 10 Attempts have been made to improve remission durations by purging the stem cell graft of tumour cells in vitro 11, 12 or in vivo, 13 but there is little evidence of improvement with current methods. The limited efficacy of highdose therapy with ASCT in MCL compared to other types of NHL may be explained either by the resistance of MCL Figure 1 No evidence of long-term remission in mantle cell lymphoma patients treated with standard high-dose chemotherapy and anti-B cell antibody-purged autologous bone marrow transplant. 10 to commonly used chemotherapeutic agents or an inability to purge contaminating tumour cells from the stem cell harvest and/or patients using current methods. These problems have been addressed in a regimen for ASCT in MCL, which combines high-dose sequential chemotherapy (sHDT) with the administration of rituximab, a human/mouse chimeric anti-CD20 antibody.
sHDT with in vivo purging sHDT with in vivo purging has been evaluated in relapsed follicular lymphoma and previously untreated MCL.
14 The regimen typically consists of two phases, a purging phase and a myeloablative phase, which together comprise a fourstep high-dose sequence of chemotherapy and six infusions of rituximab. In the purging phase the patient is administered high-dose cyclophosphamide and cytosine arabinoside, each followed by two infusions of rituximab. The myeloablative phase consists of melphalan and mitoxantrone plus melphalan, followed by two final infusions of rituximab. Overall, there are two separate stem cell harvests and three reinfusions. The first reinfusion, to support the bone marrow, occurs after high-dose Ara-C, the second following high-dose melphalan and the third following the myeloablative phase. The treatment schedule is summarised in Figure 2 and explained below.
(1) Cyclophosphamide (7 g/m 2 ) plus granulocyte colonystimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) (5 g/kg) on day 0 to begin the stem cell mobilisation process. The reinfusion of stem cells during the in vivo purging and mobilisation process allows the use of two separate cycles of high-dose chemotherapy: two such doses in close proximity might otherwise be expected to severely impair stem cell mobilisation in the harvest taken before the myeloablative phase. 15 The first harvest, however, may provide enough cells (ie у10 × 10 6 ) for all three infusions -and these cells must be lymphoma free, as measured by polymerase chain reaction (PCR). The combination of rituximab with the high-dose chemotherapy might be expected to provide a powerful means of eliminating malignant cells. Indeed, Magni et al 14 showed that in 93% of patients receiving this regimen the second stem cell harvest was negative for lymphoma cells by PCR, compared with 40% of patients receiving the identical sHDT, but without rituximab purging. All 14 evaluable patients, including six with MCL, achieved complete clinical remission.
sHDT and in vivo purging in MCL patients: preliminary results
The pilot study by Magni et al 14 suggested that sHDT with in vivo purging could improve outcomes for ASCT in CD20 + malignancies, including MCL, which have a poor prognosis even for transplanted patients. The efficacy of the regimen has now been evaluated in a further study in 28 patients with untreated MCL. Patients were given standard cytoreductive chemotherapy, followed by the four-step high-dose sequential chemotherapy regimen with two stem cell harvests and three reinfusions as described above. As in the pilot study, administration of high-dose Ara-C in close proximity to high-dose cyclophosphamide did not adversely affect the harvest of CD34 + stem cells, with one leukapheresis sufficient for the majority of patients (Table 1) .
PCR analysis of bone marrow
Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable patients, 100% lymphomanegative harvests were achieved following in vivo purging; 13 of these occurred after Ara-C administration. This is an exciting finding, contrasting sharply with previous studies where only a minority of MCL patients have yielded PCR- Table 1 Number of aphereses and CD34 + stem cell yield in 28 patients with MCL during the in vivo purging phase of sHDT
Post
Post Ara-C cyclophosphamide negative harvests. 10, 13 All assessed patients who were treated with sHDT only had lymphoma cells in the bone marrow detectable by PCR analysis.
Conversion to PCR negativity in the bone marrow following the myeloabative phase is associated with increased disease-free survival, 10 and so the PCR status of the bone marrow was monitored in these MCL patients throughout treatment as a surrogate measure of efficacy. On completion of the four-step high-dose regimen with purging and transplantation, all patients had achieved molecular remission. Molecular remissions achieved have so far been durable in those patients with long-term follow-up.
Clinical response
While molecular responses were seen in all 20 assessable patients, clinical responses were also impressive, with complete remission in 26/27 patients (97%). At a median follow-up of 22 months (range 10-42 months), one patient died because of toxicity (interstitial pneumonia, while in CR) one patient relapsed and died, while 26 were alive and disease-free. The projected event-free and overall survival at 3 years was 85%. This shows a marked improvement over what has previously been achieved in MCL, indicating that sHDT with in vivo purging offers the possibility of improving the current poor prognosis.
Conclusions
ASCT can offer the chance of improved disease-free and overall survival for patients who are not cured by chemotherapeutic regimens, but it is essential that stem cell autografts are free of contaminating tumour cells to maximise the opportunity of success. In vitro purging techniques, while usually effective in reducing the numbers of contaminating tumour cells, are limited by the constraints of time and cost: they may also delay bone marrow recovery and impair immune reconstitution through the substantial cell losses that occur. In vivo purging with rituximab has proved to be a more effective method of obtaining lymphoma-free stem cell harvests without compromising the yield or function of the stem cells. [16] [17] [18] [19] It is clear that chemotherapy, as well as rituximab, contributes to the purging effect, and patients who do not respond to chemotherapy are less likely to yield lymphomafree stem cell harvests with rituximab in vivo purging. This has been seen in MCL, which is generally poorly responsive to standard chemotherapy, and has yielded PCR negative stem cells in just 11% of patients. 13 The four-step sHDT regimen of cyclophosphamide, Ara-C, melphalan and melphalan/mitoxantrone provides a chemotherapy regimen that can be combined effectively with rituximab to clear stem cell harvests of lymphoma cells. In the pilot studies in follicular NHL and MCL, the sHDT regimen alone was effective in 40% of patients, 14 indicating that both high-dose chemotherapy and rituximab contribute to the purging effect. The use of high-dose cyclophosphamide and high-dose Ara-C in quick succession would normally be expected to seriously compromise the yield of stem cells. This problem is overcome through collection of stem cells following cyclophosphamide and reinfusion following Ara-C. This method thus allows in vivo purging with rituximab to operate in the context of an effective chemotherapy regimen.
Longer term follow-up and prospective studies are required, but the data currently available suggest that sHDT with rituximab in vivo purging may provide an effective therapy for MCL. Should this prove to be the case, the regimen may in the future be considered for first-line therapy in this disease, which responds so poorly to standard treatments.
